Sanofi lost its appeals court bid to revive patents on its blockbuster Lantus SoloStar insulin injection pen in a victory for drugmaker Viatris Inc. A review board was correct to invalidate five ...

Lantus & You journal for Lantus SoloSTAR (insulin glargine [rDNA origin] injection pen). Manufactured by Sanofi (Bridgewater, NJ). Entry submitted by IDEO (Cambridge, MA). The Lantus & You journal ...

∙ As a first result of the exclusive negotiations initiated in July, the two companies sign a global distribution agreement ∙ After an initial payment of €4 million, BIOCORP receives a new payment of ...

The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it is ...

Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (MYL +0.00%) and Biocon's Semglee, which is essentially identical to ...

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...

(Reuters) - Sanofi SA, whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices ...

The DCGI (Drugs Controller General of India) on Wednesday issued an alert regarding a stolen batch of Sanofi India's insulin formulation, Lantus SoloStar (Insulin Glargine Injection IP, r-DNA origin, ...

Credit: Getty Images. Rezvoglar may now be substituted for Lantus at the pharmacy counter without the need for an intervention from the prescriber. The Food and Drug Administration (FDA) has approved ...